Latent Tuberculosis Infection: A Guide for Primary Health Care Providers

Return to Table of Contents

References

CDC. Targeted tuberculin testing and treatment of latent TB infection. (PDF)
MMWR 2000;49 (No. RR-6).

ATS/CDC/IDSA. Treatment of tuberculosis. (PDF)
MMWR 2003;52 (No. RR-11).

CDC. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for the treatment of latent tuberculosis infection—United States, 2003. (PDF)
MMWR 2003;52(31):735-9.

CDC. Tuberculosis associated with blocking agents against tumor necrosis factor - alpha - California, 2002–2003. (PDF)
MMWR 2004; 53 (No. 30).

CDC. Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
MMWR 2004;53(2):37.

CDC. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection – United States - 2010. (PDF)
MMWR 2010;59(RR05).

CDC. Guidelines for Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children 2009: Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. (PDF)
MMWR 2009; 1-166.

CDC. Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV- Exposed and HIV-Infected Persons—2009: Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. (PDF)
MMWR 2009;58 1-198.

Reichman, LB, Bhavaraju, R, eds. Guidelines for the Diagnosis of Latent Tuberculosis Infection in the 21st Century, 2nd Edition. Newark: New Jersey Medical School Global Tuberculosis Institute